Negative depletion of CD3(+) and TcRαβ(+) T cells
- PMID: 22914586
- DOI: 10.1097/MOH.0b013e3283582340
Negative depletion of CD3(+) and TcRαβ(+) T cells
Abstract
Purpose of review: In contrast to CD34(+) positive selection, negative depletion strategies retain large numbers of effector cells in allogeneic peripheral stem cell grafts, such as natural killer (NK) and other cells. This review summarizes the clinical experience obtained using negative depletion approaches of CD3(+) and T-cell receptor (TcR)αβ(+) T lymphocytes.
Recent findings: Attempts to improve immune reconstitution and to better exploit the graft-versus-malignancy effect after transplantation of T-cell-depleted grafts through the preservation of immune effector cells led to the development of CD3-, CD3/CD19- and more recently TcRαβ/CD19-negative depletion strategies of mobilized peripheral stem cell grafts. A faster immune reconstitution has been observed in patients with negatively depleted grafts after haploidentical transplantation, although no prospective randomized trials have been reported to date. In a randomized study of matched sibling and matched unrelated transplantation, CD3/CD19-depleted peripheral stem cell grafts led to a faster recovery of NK cells compared with the CD34(+)-positive selection group.
Summary: New technologies allow the large-scale graft engineering of peripheral stem cells for clinical use in matched and mismatched stem cell transplantation. Further clinical trials are necessary to decide which of these methods is associated with a faster immune reconstitution and a better outcome after transplantation.
Similar articles
-
Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. doi: 10.1016/j.bcmd.2007.07.001. Epub 2007 Sep 14. Blood Cells Mol Dis. 2008. PMID: 17869547 Clinical Trial.
-
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.J Pediatr Hematol Oncol. 2010 Apr;32(3):e85-90. doi: 10.1097/MPH.0b013e3181cf813c. J Pediatr Hematol Oncol. 2010. PMID: 20216238
-
Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts.Leukemia. 2011 Jan;25(1):121-9. doi: 10.1038/leu.2010.235. Epub 2010 Oct 14. Leukemia. 2011. PMID: 20944677
-
Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.Immunol Lett. 2013 Sep-Oct;155(1-2):21-3. doi: 10.1016/j.imlet.2013.09.027. Epub 2013 Sep 30. Immunol Lett. 2013. PMID: 24091162 Review.
-
Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation.Ann N Y Acad Sci. 2012 Aug;1266:161-70. doi: 10.1111/j.1749-6632.2012.06606.x. Ann N Y Acad Sci. 2012. PMID: 22901267 Review.
Cited by
-
Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34+-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study.Front Immunol. 2018 Aug 14;9:1841. doi: 10.3389/fimmu.2018.01841. eCollection 2018. Front Immunol. 2018. PMID: 30154788 Free PMC article.
-
Graft Source Choice.Adv Exp Med Biol. 2025;1475:57-75. doi: 10.1007/978-3-031-84988-6_4. Adv Exp Med Biol. 2025. PMID: 40488824 Review.
-
Allo-reactive T cells for the treatment of hematological malignancies.Mol Oncol. 2015 Dec;9(10):1894-903. doi: 10.1016/j.molonc.2015.10.014. Epub 2015 Oct 24. Mol Oncol. 2015. PMID: 26578450 Free PMC article. Review.
-
The role of KIR genes and ligands in leukemia surveillance.Front Immunol. 2013 Feb 7;4:27. doi: 10.3389/fimmu.2013.00027. eCollection 2013. Front Immunol. 2013. PMID: 23404428 Free PMC article.
-
Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.Blood. 2018 Jun 14;131(24):2630-2639. doi: 10.1182/blood-2018-02-785881. Epub 2018 May 4. Blood. 2018. PMID: 29728399 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials